KORRO BIO INC

Insight: Korro Bio insider selling shows a planned exit, not panic. 41,178 shares sold at ~$14 amid a 53% decline—watch clinical milestones for a potential rebound.

Kor­ro Bio insider sales show disciplined cash management, not a loss of confidence, as SVP Dolan Oliver sells at near‑market prices while funding future clinical programs.

Insider selling spree at Korro Bio: 5,200 shares sold under Rule 10b5‑1, amid a 24.8% weekly jump to $55.89. What this means for investors.

Insightful insider sale at KORRO BIO shows COO’s routine tax‑settlement, not a confidence drop; executives keep strong long‑term stakes amid rising stock, negative earnings‑price ratio.

CEO Aiyar Ram’s recent purchase of 50,000 Korro Bio shares boosts insider confidence in its RNA‑editing OPERA platform, signaling a bullish outlook for investors.

Investor alert: Lynx1 Capital’s recent buy‑in signals confidence in Korro Bio’s rare‑disease RNA‑therapy pipeline and a potential upside as the company edges toward phase‑II trials.

Insider buying surges at Korro Bio, signaling confidence in its RNA‑editing platform and a potential upside beyond the current $11.5 price.

Insider buying spurs optimism at Korro Bio: COO & execs lock in $1.2 M in zero‑cost options, signaling confidence in RNA‑therapy pipeline and upside potential.